CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients' Survival

Cancer Invest. 2022 Mar;40(3):228-233. doi: 10.1080/07357907.2022.2028805. Epub 2022 Jan 19.

Abstract

This study was carried out to demonstrate the prognostic value of CD274 (PD-L1 promoter gene) methylation in bladder cancer patients. UCSC Xena database was searched for relevant information on PD-L1 (CD274) methylation and PD-L1 mRNA expression in bladder cancer. 407 bladder patients were included in our analyses. Multivariate analysis revealed that PD-L1 methylation was an independent predictor for OS (P = 0.037). Moreover, PD-L1 methylation might be a prognostic biomarker for immunotherapy response. However, PD-L1 methylation and PD-L1 mRNA expression was not statistically associated with chemotherapy response. In conclusion, PD-L1 methylation was an independent prognostic factor for bladder cancer patients.

Keywords: CD274; PD-L1; immunotherapy; methylation; survival.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • B7-H1 Antigen / genetics*
  • DNA Methylation*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • RNA, Messenger / analysis
  • Urinary Bladder Neoplasms / genetics
  • Urinary Bladder Neoplasms / mortality*

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • RNA, Messenger